≡

Cancer Susceptibility Candidate 4 (CASC4)

[Edit]

Cancer Susceptibility Candidate 4 (CASC4)
CCC R311
HGNC 24892
MGI 2443129
RGD 1305985
UniProt Q6P4E1
The increased expression level of CASC4 is associated with HER-2/neu proto-oncogene overexpression. Amplification and resulting overexpression of this proto-oncogene are found in approximately 30% of human breast and 20% of human ovarian cancers. Further characterization of the product of this gene may yield insight into the fundamental biology and pathogenetic effects of HER-2/neu overexpression in human breast and ovarian cancer cells. Alternatively spliced variants encoding different isoforms have been identified for this gene.
Finally, up-regulation of two of the identified cDNAs, one novel and one identified but as yet uncharacterized gene, was confirmed in human breast cancer specimens in association with HER-2/ neu overexpression.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Cancer Susceptibility Candidate 4 (CASC4) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Cancer Susceptibility Candidate 4 (CASC4) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Cancer Susceptibility Candidate 4 (CASC4) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Cancer Susceptibility Candidate 4 (CASC4) CLIA Kit Customized Service Offer
n/a ELISA Kit for Cancer Susceptibility Candidate 4 (CASC4) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Cancer Susceptibility Candidate 4 (CASC4) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Cancer Susceptibility Candidate 4 (CASC4) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Cancer Susceptibility Candidate 4 (CASC4) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Cancer Susceptibility Candidate 4 (CASC4) CLIA Kit Customized Service Offer
n/a ELISA Kit for Cancer Susceptibility Candidate 4 (CASC4) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Cancer Susceptibility Candidate 4 (CASC4) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Cancer Susceptibility Candidate 4 (CASC4) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Cancer Susceptibility Candidate 4 (CASC4) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Cancer Susceptibility Candidate 4 (CASC4) CLIA Kit Customized Service Offer
n/a ELISA Kit for Cancer Susceptibility Candidate 4 (CASC4) ELISA Kit Customized Service Offer
  1. "The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment." Genome Res. 13:2265-2270(2003) [PubMed] [Europe PMC] [Abstract]
  2. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  3. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  4. "Analysis of the DNA sequence and duplication history of human chromosome 15." Nature 440:671-675(2006) [PubMed] [Europe PMC] [Abstract]
  5. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  6. "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
  7. "N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB."Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012) [PubMed] [Europe PMC] [Abstract]
  8. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]